04952nam 2201273z- 450 991055762720332120231214132946.0(CKB)5400000000045143(oapen)https://directory.doabooks.org/handle/20.500.12854/69332(EXLCZ)99540000000004514320202105d2020 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierTuberculosis Drug Discovery and Development 2019Basel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20201 electronic resource (296 p.)3-03943-236-2 3-03943-237-0 Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million deaths in 2019, thus ranking TB among the main causes of death due to a single pathogen. Standard anti-TB therapy includes four first-line antibiotics that should be administered for at least six months. However, in the case of multi- and extensively drug-resistant TB, second-line medications must be used and these frequently cause severe side effects resulting in poor compliance. Developing new anti-TB drug candidates is therefore of outmost importance. In this Special Issue dedicated to Tuberculosis Drug Discovery and Development, we present the main and latest achievements in the fields of drug and target discovery, host-directed therapy, anti-virulence drugs, and describe the development of two advanced compounds: macozinone and delpazolid. In addition, this Special Issue provides an historical perspective focused on Carlo Forlanini, the inventor of pneumothorax for TB treatment, and includes an overview of the state-of-the-art technologies which are being exploited nowadays in TB drug development. Finally, a summary of TB vaccines that are either approved or undergoing clinical trials concludes the Special Issue.Research & information: generalbicsscBiology, life sciencesbicsscmycobacteriatuberculosismulti-drug resistancedrug discoverypromiscuous targetsMycobacterium tuberculosisrifampinisoniazidmechanisms of resistancemutationsgranulomascaseumcell envelopedormancydelpazolidmacozinoneDprE1 inhibitorclinical studiesdiscoverymode of actiondrug resistancetoxicitytargetenergy metabolismelectron transport chainoxidative phosphorylationbedaquilineQ203MID3pharmacokineticspharmacodynamicsdrug-drug interactionsin vitroin vivodrug developmenttuberculosis treatmentbiomarkersdrug combinationclinical trialBCGtuberculosis vaccinesTBVIEDCTPIAVICTVDhost-directed therapyanti-virulence compoundsTBpost-treatment sequelaesurgerypulmonary rehabilitationCarlo Forlaniniartificial pneumothoraxstructure-based drug designtarget-based drug designPknBPknGDNA gyraseantibioticmycobacteriumgenomicstranscriptomicsproteomicsmetabolomicslipidomicstarget identificationmechanism of actionantimicrobial drug resistance (AMR)target-based screeningphenotypic screeningantituberculosis agentsantimycobacterialanti-TB drug pipelineprivileged targetslead generationResearch & information: generalBiology, life sciencesRiccardi Giovannaedt535511Sala ClaudiaedtRiccardi GiovannaothSala ClaudiaothBOOK9910557627203321Tuberculosis Drug Discovery and Development 20193026529UNINA